

Cereno Scientific's patent is granted in US for use of drug candidate CS1

Cereno Scientific today announces that the US Patent Office has granted the company's patent application titled "Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation". The granted patent provides Cereno Scientific with intellectual property rights for the company's treatment concept and use of its drug candidate, CS1, in the US.

"It's very positive for us that we now have received final approval in the US, the world's largest drug market — a market that, for drug-related treatment of thrombosis alone, had estimated sales of approximately USD 10 billion 2017. The granted patent strengthens our intellectual property rights and is a strategically essential component in the commercialization of CS1, says Cereno Scientific CEO Sten R. Sörensen.

The US patent will be valid through 2035, with the possibility of a patent extension of an additional five year maximum.

For more information, please contact:

Sten R. Sörensen – CEO

Tel: +46 733 74 03 74

E-mail sten.sorensen@cerenoscientific.com

www.cerenoscientific.com

About Cereno Scientific AB

Cereno Scientific is developing a novel preventive medicine to treat thrombosis-related disease, based on the body's own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific's drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is an innovative controlled release formulation of a known compound and, as such, is expected to have a relatively short development time. The Gothenburg-based company is located in AstraZeneca's BioVentureHub and is supported by GU Ventures. Cereno Scientific's B share has been listed on Spotlight Stock Market since June 2016 with the ticker CRNO B, ISIN SE0008241558.

This information is such that Cereno Scientific AB is required to make public in accordance with the EU's market abuse regulation (MAR). The information was made available publically by the Company's contact person on October 31th 2018.

Cereno Scientific AB

Visiting address: AstraZeneca BioVentureHub Pepparedsleden 1, 431 50 Mölndal, Sweden
Postal address: Cereno Scientific AB, Erik Dahlbergsgatan 11A, SE-411 26 Göteborg, Sweden

Tel: +46 733 74 03 74, www.cerenoscientific.se